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Invited Commentary

PROceeding With the Patient-Reported Outcomes (PROs)
Version of the Common Terminology Criteria
for Adverse Events
Benjamin Movsas, MD

For more than 30 years, the standard process for reporting
toxicities in clinical oncology trials has been via the National
Cancer Institute’s (NCI’s) Common Terminology Criteria for Adverse Events (CTCAE). Overall, this system, which includes approximately 800 items, has
served our field well, such
Related article page 1051
that toxicities can be compared across clinical trials
using a consistent language. Approximately 10% of the items
represent symptoms (eg, fatigue, nausea) that are currently reported by clinicians. Prior studies, however, have shown that
there is often a disconnect, with substantial discrepancies
between patient and clinician reports of symptoms.1 This
begs the question: When it comes to reporting symptomatic
adverse events, should the perspective of the patient or the
clinician be primarily considered?
Some would argue that the clinician is most qualified to report symptomatic adverse events. After all, they have the
professional training and background to place the patient’s
symptoms into the overall context of the disease process. However, prior studies have demonstrated that, compared with patients, clinicians tend to underreport the incidence and severity of patients’ symptoms.1 Quinten et al2 provide evidence that
the accuracy of clinician-based CTCAE reporting was enhanced
by adding patient-reported outcomes (PROs) gleaned directly
from patients. At a fundamental level, how can anyone know
the patient’s subjective experience better than the patient?
Others may contend that PROs are not scientifically rigorous because they are based on subjective reporting. However, many PRO instruments (such as the European Organization for Research and Treatment of Cancer Quality of Life
Questionnaire Core 30 [EORTC QLQ-C30] and the Functional
Assessment of Cancer Therapy) have been rigorously tested for
jamaoncology.com

scientific validity and reliability.1 The fact is that much PRO research is currently hypothesis driven and based on clinically
meaningful changes using validated instruments.1 On the other
hand, the CTCAE itself was developed empirically by expert
consensus but not evaluated for validity or reliability. Indeed, limitations of the CTCAE as a psychometric instrument
to measure cancer symptom burden have previously been
described.2 In addition, PROs have often been shown to be
more powerful than standard prognosticators for predicting
survival in clinical oncology trials.1 Both the Food and Drug
Administration and NCI have adopted PROs in trials as the
benchmark for measuring subjective experiences.
In light of these considerations, the NCI decided to develop a PRO measurement system as a companion to the
CTCAE, called the PRO-CTCAE. In the article by Dueck and
colleagues3 in this issue of JAMA Oncology, the authors took on
the daunting task of analyzing the construct validity, reliability, and responsiveness of the PRO-CTCAE system, which includes a library of 124 patient self-reporting items. This study
included almost 1000 adult English-speaking patients with cancer undergoing chemotherapy and/or radiation therapy from 9
US cancer centers and community oncology practices. Patients completed the PRO-CTCAE items on tablet computers or
by telephone at 2 clinic visits, 1 to 6 weeks apart, with a subset
1 day apart. The key comparators for validation were the Eastern Cooperative Oncology Group performance status and a validated quality-of-life (QOL) instrument (EORTC-QLQ-C30). Overall, they demonstrated favorable validity, reliability, and
responsiveness of the PRO-CTCAE even in a rather diverse
sample of patients with cancer, including some with impaired
performance status. They also found significant correlations between the PRO-CTCAE item changes and the corresponding QOL
scale changes.
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Dueck and colleagues3 deserve credit for validating such
a large number of individual symptomatic toxicity items in such
a diverse group of patients with cancer. Although this is an important first step, more work is needed. For example, less than
4% of the patients in this study underwent cancer surgery, so
this group requires further study. As the authors point out, this
study included only English-speaking, US-residing patients
with cancer. Future studies will need to focus on linguistic and
cultural adaptations of PRO-CTCAE both inside and outside the
United States. The reliability data were limited to a subset of
items, such that further analysis of the test reliability will be
required. Practical issues will also need to be addressed regarding how PRO-CTCAE may affect administrative time, cost,
and patient burden over time. Beyond logistic issues, the ultimate success of the PRO-CTCAE will depend on imparting its
importance and relevance to patients, clinicians, and other
stakeholders.
The PRO-CTCAE is exciting because it is a novel patientcentered approach to adverse event (AE) reporting. By incorporating PROs into the AE reporting system, it provides a direct and unbiased account of the patient experience that can
guide future treatment recommendations. This can provide a
more accurate summary of the patient’s treatment experience, which will be relevant for labeling decisions and informing stakeholders and future users about the effects of treatment. As Basch and colleagues 4 have pointed out, a
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fundamental premise of the PRO-CTCAE project is that whereas
clinicians have the ultimate responsibility for AE reporting regarding patient safety, patients are best able to describe their
own experiences. Thus, both patients and clinicians should play
key roles in the reporting of symptomatic AEs.
In summary, the perspectives of the patients and the clinicians are indeed both essential in that they each provide
valuable and complementary input, which, when integrated,
provides a more robust appreciation of patients’ symptoms.
Clinicians contribute their professional experience to this
evaluation, while patients directly communicate their subjective experiences.4 The power of the PRO-CTCAE is that it
intertwines the patient perspective directly into the AE
reporting using a validated methodology that can facilitate
informed decision making. In the future, the PRO-CTCAE
may be used as a strategy to provide real-time information
about patients’ symptoms so that clinicians can enhance
their communication with patients regarding symptom
management. Importantly, randomized data have demonstrated that when inquiries are made regarding PROs in the
clinic, not only did physician-patient communication significantly improve, but almost all patients also expressed
interest in continuing this approach.5 One thing is reasonably clear: when it comes to optimally understanding and
appreciating the patient experience, our patients want us to
“PRO”ceed with PROs.
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